Rosetta Genomics, Ltd. (NASDAQ:ROSG)
a leading developer of microRNA-based molecular diagnostics, announced that Kenneth A. Berlin, president and chief executive officer, will be participating in a panel discussion entitled, “Issues and Opportunities in Molecular Diagnostics,” at 11:00 a.m. and will be presenting a corporate update at 1:10 p.m. at Leerink Swan’s Life Science Tools and Diagnostics Roundtable Conference being held on Thursday, August 5, 2010 at The Roosevelt Hotel in New York City.
Leerink Swan’s Roundtable Conference is a one-day meeting consisting of a series of moderated discussions with panels of MEDACorp research, clinical specialists, key members of management (CEOs, CFOs and CMOs) from the companies attending the conference, as well as institutional investors who specialize in the healthcare sector. In addition, several companies will be presenting corporate overviews.
Mr. Berlin will be available for one-on-one meetings with investors participating in the Leerink Swan Roundtable Conference. For those who would like to schedule an appointment with Rosetta Genomics’ management, please contact Anne Marie Fields, Lippert/Heilshorn & Associates, Inc., at 212-838-3777 or at
or contact your Leerink Swan representative.
About Rosetta Genomics
Rosetta Genomics is a leading developer of microRNA-based molecular diagnostics. Founded in 2000, the company’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic tools. The company’s first three microRNA-based tests, miRview™ squamous, miRview™ mets and miRview™ meso, are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab. To learn more, please visit
Various statements in this release concerning Rosetta’s future expectations, plans and prospects, including without limitation, statements relating to the development of early detection cancer screening products, including a non-invasive colon cancer screening test, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed under “Key Information - Risk Factors” in Rosetta’s Annual Report on Form 20-F for the year ended December 31, 2009 on file with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.